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Abstract
Background: To investigate the alleviation effect of Vaccinium uliginosum extract (DA9301) on tablet
computer-induced asthenopia.
Methods: This was a randomized, placebo-controlled, double-blind and parallel study (Trial registration
number: 2013–95). A total 60 volunteers were randomized into DA9301 (n = 30) and control (n = 30) groups.
The DA9301 group received DA9301 oral pill (1000 mg/day) for 4 weeks and the control group received
placebo. Asthenopia was evaluated by administering a questionnaire containing 10 questions (responses were
scored on a scales of 0–6; total score: 60) regarding ocular symptoms before (baseline) and 4 weeks after
receiving pills (DA9301 or placebo). The participants completed the questionnaire before and after tablet
computer (iPad Air, Apple Inc.) watching at each visit. The change in total asthenopia score (TAS) was
calculated and compared between the groups
Results: TAS increased significantly after tablet computer watching at baseline in DA9301 group. (from 20.35 to 23.88;
p = 0.031) However, after receiving DA9301 for 4 weeks, TAS remained stable after tablet computer watching. In the
control group, TAS changes induced by tablet computer watching were not significant both at baseline and at
4 weeks after receiving placebo. Further analysis revealed the scores for “tired eyes” (p = 0.001), “sore/aching eyes”
(p = 0.038), “irritated eyes” (p = 0.010), “watery eyes” (p = 0.005), “dry eyes” (p = 0.003), “eye strain” (p = 0.006), “blurred
vision” (p = 0.034), and “visual discomfort” (p = 0.018) significantly improved in the DA9301 group.
Conclusions: We found that oral intake of DA9301 (1000 mg/day for 4 weeks) was effective in alleviating asthenopia
symptoms induced by tablet computer watching.
Trial registration: The study is registered at www.clinicaltrials.gov (registration number: NCT02641470, date of
registration December 30, 2015).
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Background
Asthenopia or eye strain is defined as nonspecific symp-
toms of an eye when it is tired from intensive work [1].
The symptoms of asthenopia are diverse and include fa-
tigue, pain, blurred vision and headache.
Several extrinsic and intrinsic factors have been known
to cause asthenopia [1, 2]. The common causes of asthe-
nopia are, but not limited to, reading, computer work,
dry eye, presbyopia and uncorrected refractive errors. In
addition, asthenopia is one of the important subjective
symptoms for the diagnosis of dry eye syndrome [3].
Asthenopia induced by computer screen watching is
known as computer vision syndrome (CVS) [4, 5].
Symptoms that constitute CVS include ocular, visual and
musculoskeletal discomfort. Wide-spread use of mobile
devices including smart phones and tablet computers
has raised great concerns about the potential ocular side
effects caused by long-term use of these devices [6–8].
Continuous watching of computer screen is closely
related to decreased blink rate and increased accommo-
dation and convergence activities, which can lead to eye
dryness and asthenopia [9, 10]. In addition, recently
available mobile devices adopt light emitting diode
(LED) display terminals. Although LED can provide
higher resolution images, a short wavelength of light,
especially blue range light, emitted from LED can dam-
age retinal cells [11, 12]. Therefore, these all changes
occurring during computer monitor watching can mani-
fest as complex symptoms of CVS.
Vaccinium uliginosum is a flowering plant native to
low-temperature regions of the Northern Hemisphere. It
is found in the Alps, the Pyrenees, the Caucasus in
Europe as well as in Mongolia, China, Japan and Korea
[13]. The extract of Vaccinium uliginosum fruit contains
abundant antioxidant compounds such as anthocyanins
and flavonoids [14, 15]. Antioxidants supplementation
has been known as effective in alleviating dry eye symp-
toms [16–18]. In addition, the extract of Vaccinium
uliginosum demonstrated protective effect of retinal cells
in light-induced retinal damage [19]. Considering its an-
tioxidative constituents and previous evidences of retinal
protection, we hypothesize that the extract of Vaccinium
uliginosum will be useful in treating various ocular path-
ologies including computer vision syndrome.
We performed a randomized, placebo-controlled study
in healthy subjects and investigated the protective effect
of Vaccinium uliginosum extract (DA-9301) on tablet
computer-induced asthenopia.
Methods
Study design and population
This is a randomized, placebo-controlled, double-blind,
parallel design study. The study was conducted at Clinical
Research Center located in Ilsan Hospital, Dongguk
University, Goyang, South Korea and followed the tenets
of the Declaration of Helsinki and was approved by the in-
stitutional review board (IRB) of Ilsan Hospital, Dongguk
University (IRB approval number: 2013–95). The study is
registered at www.clinicaltrials.gov (registration number:
NCT 02641470). Written informed consents were ob-
tained from participants before their enrollment. The
screening for the first volunteer was started on February,
2014 and the whole study was ended on May, 2014.
Sixty two volunteers were screened and 60 eligible vol-
unteers were randomized. The inclusion criteria were
healthy subject aged 20–65 years with more than 2 h of
daily use of a smart phone or computer including a
tablet and television. Exclusion criteria are listed in
Table 1. After passing the screening test (two subjects
were excluded as screening failure), 60 subjects were
Table 1 Exclusion criteria
-Ocular disease in either eye
a. Ocular surface disease
Corneal fluorescein staining grade ≥3
Tear film break up time <5 s
Schirmer I (without anesthetic) test <5 mm
b. Best corrected visual acuity < 20/30
c. Intraocular pressure > 21 mmHg
d. Optical coherence tomography proven retinal nerve fiber defect
e. Significant cataract (lens opacities classification system III: ≥NO3/
NC3, ≥C3 or≥ P3)
f. Significant entropion or ectropion
g. Significant tear drainage problem proved with fluorescein dye
dilution test
-Soft or Hard contact lens use 3 or more days a week
-History of oral intake of health supplement designed to improve
asthenopia within 4 weeks before participating this study
-Regular use of any lubricant eye drops
-Pregnant woman
-Systemic disease
a. Uncontrolled hypertension (systolic/diastolic blood pressure >
140/90 mmHg)




e. Active hepatitis (type B and C)
f. Acute or chronic infectious disease
g. Renal disease
Fig. 1 Schematic design of the study
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randomized to study (DA9301) and control groups in
double blinded manner at a ratio of 1:1. The randomization
codes were generated using a block algorithm by a statisti-
cian and the seed number for the algorithm was the date
that the codes were created. The study group received
DA9301 pills (1000 mg/day) for 4 weeks and the control
group received placebo (same shape, size, and color as
those of the DA9301 pill). (Figure 1) Now the study group
is referred as DA9301 throughout the manuscript. Compli-
ance was measured both by reviewing the drug intake diary
and by counting remnant pills at the final visit. If the
compliance failed to reach 80 %, the participants were
excluded. In addition, any participants who took forbidden
systemic medications such as antihistamines, anticholiner-
gics, thyroid hormones, anti-thyroid drugs and Ginko
biloba extracts were excluded. These medications were
forbidden because they may affect ocular surface condition
during the study period [20–23].
Preparation of Vaccinium ulginosum extract (DA9301)
The fruits of Vaccinium uliginosum was washed and
extracted with water at 60 ~ 70 °C, and the extracts were
subsequently went through diatomaceous earth filtra-
tion. The filtered extracts were concentrated and steril-
ized at 50 °C, 60 ~ 65brix. Diluent (Maltodextrin) was
added to the extracts and sterilized again at 80 ~ 95 °C
for 10 min for two times. And it was spray-dried. The
marker compound of Vaccinium uliginosum is total
Table 2 Asthenopia questionnaire form modified from the
original version proposed by Ames et al.
Symptom None Slight Moderate Severe
Tired eyes 0 1 2 3 4 5 6
Sore/aching eyes 0 1 2 3 4 5 6
Irritated eyes 0 1 2 3 4 5 6
Watery eyes 0 1 2 3 4 5 6
Dry eye 0 1 2 3 4 5 6
Eye strain 0 1 2 3 4 5 6
Hot/burning eyes 0 1 2 3 4 5 6
Blurred vision 0 1 2 3 4 5 6
Difficult focusing 0 1 2 3 4 5 6
Visual discomfort 0 1 2 3 4 5 6
Fig. 2 Flowchart (CONSORT) of the participants throughout the study. N: number
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polyphenols. Its content is approximately 9.1 mg/g, accept-
able within a range (80 % to 120 %).
Preparation of DA9301 and placebo pills
The DA9301 pill was prepared by mixing DA9301
(500 mg), lactose (56.63 mg) and crystal cellulose. The
placebo pill only contained lactose (556.63 mg). The
shape, size, and color of both the DA9301 and placebo
pills were the same.
Ophthalmic screening test
Ophthalmic screening for participants included slit lamp
microscopy, non-contact intraocular pressure measure-
ment, fundus photography, corrected distance visual
acuity, Schirmer’s test, and tear-film break-up time.
Tablet computer screen stimulus
Participants in the DA9301 and control groups were asked
to watch a table computer screen (iPad Air, Apple Inc.,
Cupertino, CA) for 1 h at a viewing distance of 40 cm at
baseline and 4-week visits. Participants watched a movie
or played a computer game on the tablet computer. Those
with presbyopia were allowed to use reading glasses for
their comfort. For exact comparisons, subjects who
watched a movie or played a game at baseline visit were
asked to repeat the task at 4 week visit. Tablet computer
screen stimulation was performed in the same room dur-
ing all the study period to consistently maintain the hu-
midity, temperature and illumination; the humidity and
temperature were checked on every study day.
Outcome measures
Asthenopia was evaluated by using a modified question-
naire proposed by Ames et al. (Table 2) [24]. These ques-
tionnaires contained 10 questions related to asthenopia
that needed to be responded to using a scale of 0–6, with
0 defined as none and 6 as most severe. Most severe asth-
enopia corresponded to a score of 60. All subjects
completed the questionnaire before and immediately after
tablet computer use. The severity of asthenopia may
change depending on daily body condition including
diurnal variation and environmental factors such as illu-
mination, humidity and room temperature [2, 25]. There-
fore, to compare the effect of tablet computer watching,
the asthenopia scores before and immediately after tablet
computer watching (induced asthenopia) were calculated
and score change was compared between the DA9301 and
control groups. For objective measurement of ocular
dryness and visual deterioration, tear film break-up time
and total high order wavefront aberration (Wavescan,
VISX/Advanced Medical Optics, Santa Clara, CA) were
measured in the right eyes before and after tablet com-
puter watching. The measurements were made triplicate
and the mean values were used for the analysis.
Table 3 Comparison of demographic characteristics between
the DA9301 and placebo groups
Treatment Group p-value
DA9301 Placebo
n = 26 n = 24
Sex, n (%) n % n %
Male 12 63.16 7 36.84 0.216*
Female 14 45.16 17 54.84
Smoking, n (%) n % n %
no 23 (5) 46.15 23 (2) 53.85 0.312***
yes 3 75.00 1 25.00
in the past 5 71.43 2 28.57
Drinking, n (%) n % n %
no 8 53.33 7 46.67 0.902*
yes 18 51.43 17 48.57
Age (yr)
Mean (SD) 39.85 (11.35) 38.04 (9.92) 0.277**
Median
(Min, Max)
38.00 (22.00,64.00) 39.00 (22.00,59.00)
Height (cm)
Mean (SD) 166.08 (9.32) 164.02 (9.04) 0.216**
Median
(Min, Max)
165.65 (150.10,192.00) 161.30 (150.10,179.40)
Weight (kg)
Mean (SD) 66.85 (12.00) 61.05 (12.56) 0.015****
Median
(Min, Max)
65.95 (47.70,93.40) 56.25 (45.50,101.30)
*:p-value obtained from Chi-square test. If p-value < 0.05, then significant
**:p-value obtained from Student’s t-test. If p-value < 0.05, then significant
***p-value obtained from Fisher’s exact test. If p-value < 0.05, then significant
****:p-value obtained from Wilcoxon’s rank sum test. If p-value < 0.05,
then significant
Table 4 Change in total score of asthenopia questionnaire after
tablet computer watching was compared




n = 26 n = 24
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*:p-value obtained from Student,s t-test. If p-value < 0.05, then significant
**:p-value obtained from Paired t-test. If p-value < 0.05, then significant
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Table 5 The change of score for each asthenopia question after




n = 26 n = 24
Tired eyes Baseline visit 0.124



































Irritated eyes Baseline visit 0.308
















Watery eyes Baseline visit 0.072
















Dry eyes Baseline visit 0.024
















Table 5 The change of score for each asthenopia question after
tablet computer watching was compared between baseline and
final visits (Continued)
Eye strain Baseline visit 0.072



































Blurred vision Baseline visit 0.193




















































*:p-value obtained from Student's t-test. If p-value < 0.05, then significant
**:p-value obtained from Paired t-test. If p-value < 0.05, then significant
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Dietary antioxidant measurement
Participants presented the last 3 days diet before the
4 week visit. Nutritional components within diet were
analyzed by using computer aided nutritional analysis
program (CAN) pro v4.0 devised by Korean Nutrition
Society. Vitamins C and E, beta-carotene and selenium
were selected as potential antioxidant nutrients and their
uptake was compared between DA 9301 and placebo
groups.
Statistical analysis
A total of 50 patients (25 patients in each group)
were needed to achieve 80 % power and to detect a
difference of 0.72 in the total score of asthenopia
questionnaire. To allow for 15 % drop-out rate, we
randomly assigned 30 participants to each group
(study vs. control). Statistical analysis was performed
using SAS® (Version 9.3, SAS Institute, Cary, NC). An
assessment of normality of data was assessed by using
Shapiro-Wilk test. The comparisons between the
study groups were performed with the use of Stu-
dent’s t-test (or Wilcoxon’s rank sum test) and paired
t-test (or Wilcoxon’s signed rank test) for continuous
data and the chi-square test or Fisher’s exact test for
categorical data.
Results
Twenty-nine participants in the DA9301 group and 30
participants in the placebo group completed the final
visit evaluation. Treatment compliance was 96.75 ±
5.06 % in the DA9301 group and 95.92 ± 6.60 % in the
placebo group (p = 0.309, Wilcoxon’s rank sum test).
One participant in each group was excluded owing to
poor compliance. Two participants in the DA9301 group
and five participants in the placebo group were excluded
owing to the use of prohibited medicines during the
study period. Data from 26 participants in the DA9301
group and 24 participants in the placebo group were
used for the final analyses (Fig. 2).
Comparison of demographic characteristics between
the two groups showed no significant differences in any
parameter except body weight (Table 3).
Total asthenopia score (TAS) change induced by tablet
computer watching was determined both at the baseline
and the final visits. Table 4 presents the changes of TAS
by tablet computer watching at the baseline and the final
visits. Watching tablet computer at the baseline visit
increased TAS by 3.54 and 1.04 in the DA9301 and
placebo groups, respectively. The change of TAS in the
DA9301 group was statistically significant, while that of
placebo group was not significant. It is noteworthy that
the mean TAS change at the final visit showed a mean
TAS increase of 0.46 and 2.42 in the DA9301 and
placebo groups, respectively and this difference was sig-
nificant (p = 0.039, DA9301 baseline visit vs. DA9301
final visit; p = 0.020, DA9301 vs. placebo).
We further analyzed each questionnaire of TAS to
determine the effect of DA9301. In the DA9301 group,
the score changes for 8 of the 10 questions suggested
significant improvement and these include questions
pertaining to “tired eyes” (p = 0.001), “sore/aching
eyes” (p = 0.038), “irritated eyes’”(p = 0.010), “watery
eyes” (p = 0.005), “dry eyes” (p = 0.003), “eye strain”
(p = 0.006), “blurred vision” (p = 0.035), and “visual
discomfort” (p = 0.018). (Table 5) The placebo group
showed improved scores only for “tired eyes” (p = 0.002)
and “irritated eyes” (p = 0.033). It is noteworthy that the
score improvement for “dry eyes” showed significant dif-
ference when comparing the DA9301 and placebo groups
possibly indicating a more prominent DA9301 effect on
“‘dry eyes” (p = 0.024) (Table 5).
There was no significant change of tear film break-up
time and total high order wavefront aberration when
comparing before and after tablet computer watching in
both groups (Tables 6 and 7).
There were no significant ocular and systemic compli-
cations related to this study in both DA9301 and control
groups. Dietary antioxidant consumption between two
groups showed no significant difference (Table 8).
Table 6 Change of tear film break-up time (seconds) before and after tablet computer watching was compared
Treatment Group
DA9301 Placebo
n = 26 n = 24
Before video stimulus After video stimulus p-value Before video stimulus After video stimulus p-value
Baseline visit
Mean (SD) 4.90 (1.50) 4.60 (1.21) 0.893 5.20 (1.55) 4.62 (1.46) 0.989
Median (Min, Max) 4.50 (3, 8) 4.30 (3, 7.3) 5.15 (3, 9.3) 4.15 (2.3,9.3)
Final visit
Mean (SD) 4.78 (1.50) 4.34 (1.04) 0.963 4.67 (1.20) 4.35 (0.92) 0.972
Median (Min, Max) 4.65 (2.3,7.7) 4.15 (3,7) 4.5 (2.7,7.3) 4.3 (3,6.7)
p-value obtained from one-sided paired t-test. If p-value < 0.05, then significant
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Discussion
Recent advances in smart mobile devices have
increased the popularity of smart phones and tablet
computers among the general population. With the
wide-spread use of smart mobile devices, smart device
addiction has become serious health problem world-
wide [6, 26]. Continuous accommodation is necessary
to focus on the display of smart mobile devices for an
extended period. The fatigue induced by video monitors,
such as LCD and LED monitors, has been previously re-
ferred as computer vision syndrome (CVS) [4, 5, 27, 28].
About 64–90 % of computer users develop CVS [4]. It has
been reported that blink rate during computer work sig-
nificantly decreases and negatively correlates with eye
discomfort score [10]. Another study revealed that com-
puter work for more than 4 h significantly increased eye
discomfort [29]. In addition, electronic book readers with
LCD monitor cause marked visual fatigue [30].
Our results have demonstrated the aggravation of CVS
upon viewing monitors such as those of mobile devices.
A recent study demonstrated that the preferred distance
for viewing a mobile device (36.2 cm) is shorter than the
typical distance for reading books (40 cm) and this re-
quires more accommodation and convergence [31]. The
cumulative effect of continuous accommodation and
convergence can manifest as various ocular, visual and
musculoskeletal symptoms which are collectively called
as asthenopia.
Various methods of treatment have been suggested to
manage CVS. These include correction of residual refract-
ive errors, instillation of artificial tears, combination of
specific body posture, breathing and mental control, visual
ergonomics and Ayurveda medicine [28, 32–34]. There
are anecdotal reports about the effectiveness of these
treatment modalities. Specific pharmacologic intervention
to alleviate asthenopia induced by CVS has been investi-
gated previously. Omega-3 fatty acid was reported to de-
crease visual discomfort in CVS by decreasing tear
evaporation and improving dry eye symptoms [35]. Top-
ical brief application of polyphenol on eyes alleviated eye
fatigue after computer work [36]. It is also important to
maintain baseline efforts such as taking regular break,
Table 8 Comparison of dietary antioxidant components between DA9301 and placebo group during the last three days before the
4-week visit
DA9301 (n = 26) Placebo (n = 24) p-value
Vitamin C (mg)
Mean (SD) 177.94 (85.87) 209.02 (114.14) 0.275
Median (Min, Max) 171.81 (54.72, 369.20) 188.58 (58.98, 577.18)
Vitamin E (mg)
Mean (SD) 37.01 (12.50) 36.72 (12.62) 0.935
Median (Min, Max) 35.11 (19.16,62.04) 33.53 (18.28,76.56)
ß- carotene (mg)
Mean (SD) 7771.03 (4323.44) 7342.58 (2939.67) 0.682
Median (Min, Max) 6976.01 (1407.43, 18856.67) 6775.62 (2432.26,14648.82)
Selenium (μg)
Mean (SD) 239.75 (77.62) 214.80 (55.19) 0.193
Median (Min, Max) 234.90 (126.29,383.19) 214.60 (128.88,361.70)
p-value obtained from two sample t-test. If p-value < 0.05, then significant
Table 7 Change of total high order wavefront aberration (μm) before and after tablet computer watching was compared
Treatment Group
DA9301 Placebo
n = 26 n = 24
Before video stimulus After video stimulus p-value Before video stimulus After video stimulus p-value
Baseline (Visit 2)
Mean (SD) 2.33 (2.05) 2.32 (1.90) 0.451 2.51 (2.46) 2.61 (2.62) 0.856
Median (Min, Max) 1.55 (0.31,7.08) 1.7 (0.23,6.50) 1.49 (0.36,9.14) 1.4 (0.35,9.97)
Visit 3
Mean (SD) 2.18 (1.83) 2.27 (1.93) 0.715 2.49 (2.36) 2.53 (2.33) 0.633
Median (Min, Max) 1.53 (0.42,5.95) 1.7 (0.27,6.92) 1.92 (0.27,7.69) 1.8 (0.36,7.74)
p-value obtained from one-sided paired t-test. If p-value < 0.05, then significant
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proper refractive correction, and treating underlying ocu-
lar surface disease to prevent CVS.
In this study, we found that oral intake of DA9301 for
4 weeks significantly alleviated visual discomfort induced
by tablet computer work. The exact mechanism of the
action of DA9301 needs further investigation. However, as
mentioned earlier, DA9301 contains antioxidant ingredients
such as anthocyanins and flavonoids [31]. It has been
recently reported that Vaccinium uliginosum extract
prevented the blue light-induced human retinal pigment
epithelial cell death by inhibiting photo-oxidation of N-
retinyl-N-retinylidene ethanolamine [37]. Extract of V.
uliginosum partially preserved the outer nuclear layer of
retina after light damage [19]. Another study reported the
positive effect of V. uliginosum extract on improving learn-
ing and memory impairment in murine Alzheimer’s disease
model [38]. The symptoms of dry eye disease and astheno-
pia partially overlap [3]. Previous studies have demon-
strated the beneficial effect of antioxidants in alleviating dry
eye disease [16–18]. We hypothesize that a similar mechan-
ism might be involved in the DA9301-induced alleviation
of asthenopia in our study.
There are several limitations of this study. First, we
used questionnaires to evaluate the effect of DA9301.
The responses to the questionnaire are somewhat sub-
jective and could be affected by responders’ daily phys-
ical and mental condition. It would be better to adopt an
objective measurement of asthenopia. It is noteworthy
that a new questionnaire to assess computer vision
symptom was recently developed and now is under
validation [39]. However, to the best of our knowledge,
there is no established objective method to quantify
asthenopia, although tear film break-up time and wave-
front aberration were used as an possible objective
method in our study. Second, the tablet computer stimu-
lus employed in our study is shorter (1 h) than that in a
typical CVS model (several hours of intensive computer
work). This could explain the relatively mild TAS
increase observed in our study. More prolonged and in-
tense computer work could aggravate TAS. Another
limitation of this study is the lack of eye exercises
screening of the participants. Recently, awareness
regarding the eye disorders is on the rise and many
people are doing regular eye exercises which can have
significant impact on the study. In addition, although
DA9301 was found to significantly alleviate asthenopia
induced by table computer watching, a reverse trial of
DA9301 and placebo (applying DA9301 in placebo
group and vice versa) after a washout period may signifi-
cantly enhance the strength of our result.
Conclusions
Oral intake of DA9301 was effective in alleviating CVS in-
duced by a tablet computer and this could be attributed to
its strong antioxidant potential. Further investigation of the
mechanisms underlying the effect of DA9301 is warranted.
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